Obesity and Nonalcoholic Fatty Liver Disease
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Gastrointestinal, Gastrointestinal |
| Therapuetic Areas: | Endocrinology, Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 7/13/2018 |
| Start Date: | October 2004 |
| End Date: | December 2008 |
The primary goal of this study is to provide a better understanding of: 1) the pathogenesis
and pathophysiology of non-alcoholic fatty liver disease (NAFLD) in obese subjects, and 2)
the effect of marked weight loss on the histologic and metabolic abnormalities associated
with NAFLD. The following hypotheses will be tested:
1. obesity causes hepatic fat accumulation because of excessive fatty acid release from fat
tissue and increased free fatty acid availability,
2. increased hepatic (liver) fat content causes insulin-resistant glucose (sugar)
production by the liver and altered liver protein synthesis,
3. increased hepatic fat content causes increased lipid (fat) peroxidation, hepatic
inflammation, necrosis and fibrosis, and
4. marked weight loss improves NAFLD once patients are weight stable.
and pathophysiology of non-alcoholic fatty liver disease (NAFLD) in obese subjects, and 2)
the effect of marked weight loss on the histologic and metabolic abnormalities associated
with NAFLD. The following hypotheses will be tested:
1. obesity causes hepatic fat accumulation because of excessive fatty acid release from fat
tissue and increased free fatty acid availability,
2. increased hepatic (liver) fat content causes insulin-resistant glucose (sugar)
production by the liver and altered liver protein synthesis,
3. increased hepatic fat content causes increased lipid (fat) peroxidation, hepatic
inflammation, necrosis and fibrosis, and
4. marked weight loss improves NAFLD once patients are weight stable.
Obesity is a major risk factor for non-alcoholic fatty liver disease (NAFLD), which
represents a spectrum of liver diseases. NAFLD is a major health problem in the US because of
its high prevalence and causal relationship with serious liver abnormalities. However, the
mechanism(s)responsible for developing NAFLD in obese persons and the effects on liver
function are not known. This gap in knowledge has made it difficult to identify effective
therapy. The results from these studies will lay the groundwork for the development of novel
therapeutic interventions for NAFLD in obese patients.
represents a spectrum of liver diseases. NAFLD is a major health problem in the US because of
its high prevalence and causal relationship with serious liver abnormalities. However, the
mechanism(s)responsible for developing NAFLD in obese persons and the effects on liver
function are not known. This gap in knowledge has made it difficult to identify effective
therapy. The results from these studies will lay the groundwork for the development of novel
therapeutic interventions for NAFLD in obese patients.
Inclusion Criteria:
All
- 18 - 45 years old
- Class I obesity, i.e. Body Mass Index (BMI) between 30 and 45.
- weight less than 300 lbs.
Exclusion Criteria:
- Active or previous infection with hepatitis B or C, as well as other liver disease.
- History of alcohol abuse
- Diabetes
- Medications that cause liver damage or steatosis.
- Women who are pregnant or lactating.
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
